Arcturus Therapeutics Announces Agreement with Israeli Ministry of Health to Supply COVID-19 Vaccine Candidate, LUNAR-COV19
July 23, 2020 16:01 ET
|
Arcturus Therapeutics Holdings Inc.
Israel secures rights to stockpile and reserve doses of LUNAR-COV19 for its citizens Israel is the second country to reserve supply of LUNAR-COV19 SAN DIEGO, July 23, 2020 (GLOBE NEWSWIRE) --...
Arcturus Therapeutics & Duke-NUS Received Approval to Proceed with Phase 1/2 Clinical Trial for COVID-19 Vaccine Candidate, LUNAR-COV19
July 21, 2020 08:30 ET
|
Arcturus Therapeutics Holdings Inc.; Duke-NUS Medical School
Human dosing of LUNAR-COV19 expected soon Differentiated STARR™ mRNA vaccine expected to produce humoral and cellular immunity at very low doses New preclinical data demonstrates neutralizing...
Arcturus Therapeutics Announces the Formation of its Vaccine Platform Scientific Advisory Board
July 01, 2020 08:00 ET
|
Arcturus Therapeutics Holdings Inc.
Renowned experts in virology, infectious disease, vaccine development and public health to support Arcturus’ COVID-19 vaccine program, LUNAR-COV19 Company remains on track to begin clinical...
Arcturus Therapeutics to be Added to Russell 2000® Index
June 29, 2020 08:00 ET
|
Arcturus Therapeutics Holdings Inc.
SAN DIEGO, June 29, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the...
Arcturus Therapeutics to Present at the Raymond James Human Health Innovation Virtual Conference
June 11, 2020 08:00 ET
|
Arcturus Therapeutics Holdings Inc.
SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the...
Arcturus Therapeutics Announces First Healthy Volunteer Dosed in Phase 1 Study of ARCT-810 for Ornithine Transcarbamylase (OTC) Deficiency
June 05, 2020 08:00 ET
|
Arcturus Therapeutics Holdings Inc.
SAN DIEGO, June 05, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the...
Arcturus Reports Additional Supportive Preclinical Data for its COVID-19 Vaccine Candidate (LUNAR-COV19)
May 08, 2020 09:30 ET
|
Arcturus Therapeutics Holdings Inc.
New data provides evidence of adaptive cellular (CD8+ cells) and balanced (Th1/Th2) immune responses STARR™ mRNA elicits anti-spike protein antibodies (IgG), higher than conventional mRNA at all...
Arcturus Therapeutics Announces First Quarter 2020 Financial Results and Provides a Corporate Update
May 07, 2020 16:01 ET
|
Arcturus Therapeutics Holdings Inc.
Important progress advancing COVID-19 STARR™ mRNA vaccine candidate (LUNAR-COV19);New preclinical data demonstrate robust immunogenicity with a single, low dose Company remains on track to begin...
Arcturus Therapeutics to Report First Quarter 2020 Financial Results and Provide a Corporate Update on May 7, 2020
May 04, 2020 15:00 ET
|
Arcturus Therapeutics Holdings Inc.
SAN DIEGO, May 04, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the...
Arcturus Therapeutics and Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 Vaccine
May 04, 2020 08:39 ET
|
Arcturus Therapeutics Holdings Inc.
SAN DIEGO and SOMERSET, N.J., May 04, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (“Arcturus”, “the Company”, Nasdaq: ARCT), a leading clinical-stage messenger RNA (mRNA) medicines...